$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

$halo Overview Financials Valuation SEC Filings Company Website

2014 Q4 Form 10-K Financial Statement

#000115903615000041 Filed on March 02, 2015

Income Statement

Concept	2014 Q4	2013 Q4	2013 Q3
Revenue	$30.38M	$12.50M	$16.01M
YoY Change	143.04%	-42.65%	200.19%
Cost Of Revenue	$6.100M	$3.500M	$683.0K
YoY Change	74.29%	400.0%	201.37%
Gross Profit	$3.997M	$6.266M	$9.342M
YoY Change	-36.21%	677.56%	1811.53%
Gross Profit Margin	13.16%	50.13%	58.34%
Selling, General & Admin	$8.400M	$9.400M	$8.135M
YoY Change	-10.64%	34.29%	44.39%
% of Gross Profit	210.16%	150.02%	87.08%
Research & Development	$19.70M	$20.90M	$25.69M
YoY Change	-5.74%	12.37%	31.71%
% of Gross Profit	492.87%	333.55%	274.98%
Depreciation & Amortization	$500.0K	$300.0K	$300.0K
YoY Change	66.67%	0.0%	0.0%
% of Gross Profit	12.51%	4.79%	3.21%
Operating Expenses	$28.10M	$30.30M	$33.82M
YoY Change	-7.26%	18.82%	34.56%
Operating Profit	-$24.10M	-$24.03M	-$18.49M
YoY Change	0.29%	-2.67%	-7.67%
Interest Expense	-$1.400M	-$700.0K	$850.0K
YoY Change	100.0%
% of Operating Profit
Other Income/Expense, Net			$52.00K
YoY Change			116.75%
Pretax Income	-$5.300M	-$22.00M	-$19.30M
YoY Change	-75.91%	400.0%	-3.5%
Income Tax		$0.00	$0.00
% Of Pretax Income
Net Earnings	-$5.274M	-$21.99M	-$19.29M
YoY Change	-76.01%	399.02%	-3.57%
Net Earnings / Revenue	-17.36%	-175.9%	-120.48%
Basic Earnings Per Share
Diluted Earnings Per Share	-$42.64K	-$193.7K	-$171.1K
COMMON SHARES
Basic Shares Outstanding	125.4M shares	114.0M shares	113.3M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2014 Q4	2013 Q4	2013 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$135.6M	$71.50M	$65.30M
YoY Change	89.65%	-28.14%	-25.46%
Cash & Equivalents	$61.39M	$27.36M	$17.49M
Short-Term Investments	$74.20M	$44.10M	$47.80M
Other Short-Term Assets	$10.10M	$8.400M	$9.100M
YoY Change	20.24%	-34.38%	-20.18%
Inventory	$6.406M	$6.170M	$3.846M
Prepaid Expenses
Receivables	$9.149M	$9.097M	$24.52M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$161.3M	$95.20M	$102.8M
YoY Change	69.46%	-27.13%	-2.63%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.951M	$3.422M	$4.936M
YoY Change	-13.76%	-7.53%	105.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.700M	$3.200M	$2.400M
YoY Change	-46.88%	700.0%
Total Long-Term Assets	$4.656M	$6.598M	$7.327M
YoY Change	-29.43%	60.91%	205.3%
TOTAL ASSETS
Total Short-Term Assets	$161.3M	$95.20M	$102.8M
Total Long-Term Assets	$4.656M	$6.598M	$7.327M
Total Assets	$166.0M	$101.8M	$110.1M
YoY Change	63.05%	-24.45%	1.99%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.003M	$3.135M	$5.592M
YoY Change	-4.21%	38.0%	59.76%
Accrued Expenses	$13.96M	$14.37M	$20.62M
YoY Change	-2.84%	84.61%	157.81%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$0.00	$5.970M
YoY Change
Total Short-Term Liabilities	$24.33M	$24.90M	$39.62M
YoY Change	-2.29%	31.44%	88.68%
LONG-TERM LIABILITIES
Long-Term Debt	$49.86M	$49.77M	$26.30M
YoY Change	0.18%	67.8%
Other Long-Term Liabilities	$3.167M	$1.364M	$921.5K
YoY Change	132.18%		-97.43%
Total Long-Term Liabilities	$53.03M	$51.14M	$921.5K
YoY Change	3.7%	72.4%	-97.43%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.33M	$24.90M	$39.62M
Total Long-Term Liabilities	$53.03M	$51.14M	$921.5K
Total Liabilities	$77.36M	$76.04M	$40.55M
YoY Change	1.74%	56.43%	-28.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$450.4M	-$382.1M	-$360.1M
YoY Change	17.9%	27.96%
Common Stock	$491.8M	$362.0M	$356.6M
YoY Change	35.84%	4.21%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.35M	-$19.99M	-$3.486M
YoY Change
Total Liabilities & Shareholders Equity	$166.0M	$101.8M	$110.1M
YoY Change	63.05%	-24.45%	1.99%

Cashflow Statement

Concept	2014 Q4	2013 Q4	2013 Q3
OPERATING ACTIVITIES
Net Income	-$5.274M	-$21.99M	-$19.29M
YoY Change	-76.01%	399.02%	-3.57%
Depreciation, Depletion And Amortization	$500.0K	$300.0K	$300.0K
YoY Change	66.67%	0.0%	0.0%
Cash From Operating Activities	-$900.0K	-$15.20M	-$12.40M
YoY Change	-94.08%	-10.06%	-13.29%
INVESTING ACTIVITIES
Capital Expenditures	-$300.0K	-$1.400M	-$300.0K
YoY Change	-78.57%	180.0%	50.0%
Acquisitions
YoY Change
Other Investing Activities	$13.70M	$3.300M	$0.00
YoY Change	315.15%
Cash From Investing Activities	$13.40M	$2.000M	-$300.0K
YoY Change	570.0%	-500.0%	50.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	2.500M	23.10M	2.300M
YoY Change	-89.18%	-22.22%	2200.0%
NET CHANGE
Cash From Operating Activities	-900.0K	-15.20M	-12.40M
Cash From Investing Activities	13.40M	2.000M	-300.0K
Cash From Financing Activities	2.500M	23.10M	2.300M
Net Change In Cash	15.00M	9.900M	-10.40M
YoY Change	51.52%	-19.51%	-27.78%
FREE CASH FLOW
Cash From Operating Activities	-$900.0K	-$15.20M	-$12.40M
Capital Expenditures	-$300.0K	-$1.400M	-$300.0K
Free Cash Flow	-$600.0K	-$13.80M	-$12.10M
YoY Change	-95.65%	-15.85%	-14.18%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2014	dei	Amendment Flag AmendmentFlag	false
CY2014	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2014	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2014
CY2014	dei	Document Period End Date DocumentPeriodEndDate	2014-12-31
CY2014	dei	Document Type DocumentType	10-K
CY2014	dei	Entity Central Index Key EntityCentralIndexKey	0001159036
CY2015Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	126704135	shares
CY2014	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2014	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2014Q2	dei	Entity Public Float EntityPublicFloat	1000000000	USD
CY2014	dei	Entity Registrant Name EntityRegistrantName	HALOZYME THERAPEUTICS INC
CY2014	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2014	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2013Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	3707000	USD
CY2014Q4	halo	Accountsreceivablefromcollaborators Accountsreceivablefromcollaborators	1266000	USD
CY2013Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	1505000	USD
CY2014Q4	halo	Accountsreceivablefromproductsales Accountsreceivablefromproductsales	2133000	USD
CY2013Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	4495000	USD
CY2014Q4	halo	Accountsreceivablefromproductsalestocollaborators Accountsreceivablefromproductsalestocollaborators	6361000	USD
CY2013Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	3377000	USD
CY2014Q4	halo	Accrued Outsourced Research And Development Expenses Current AccruedOutsourcedResearchAndDevelopmentExpensesCurrent	4383000	USD
CY2013Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	551000	USD
CY2014Q4	halo	Accrued Outsourced Researchand Development Expenses Long Term AccruedOutsourcedResearchandDevelopmentExpensesLongTerm	480000	USD
CY2013Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	3233000	USD
CY2014Q4	halo	Accruedmanufacturingexpenses Accruedmanufacturingexpenses	2112000	USD
CY2014Q4	halo	Additional Maximum Proceeds Receivablefrom Collaboratorof Licenseand Collaborative Agreement Upon Achievementof Clinical Development Milestones AdditionalMaximumProceedsReceivablefromCollaboratorofLicenseandCollaborativeAgreementUponAchievementofClinicalDevelopmentMilestones	55000000	USD
CY2014Q4	halo	Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets Additionalmaximumcashpaymentsreceivableuponachievementofregulatorymilestonesforelectedtargets	12000000	USD
CY2013Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	610000	USD
CY2014Q4	halo	Allowancefor Distribution Feesand Discounts AllowanceforDistributionFeesandDiscounts	611000	USD
CY2014	halo	Contingentmilestonepayment Contingentmilestonepayment	9300000	USD
CY2012	halo	Foreignbasedoperations Foreignbasedoperations	0
CY2013	halo	Foreignbasedoperations Foreignbasedoperations	0
CY2014	halo	Foreignbasedoperations Foreignbasedoperations	0
CY2012	halo	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	45000	USD
CY2013	halo	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-48000	USD
CY2014	halo	Increase Decrease In Deferred Rent IncreaseDecreaseInDeferredRent	-15000	USD
CY2014Q4	halo	Long Term Debt Including Interest Gross LongTermDebtIncludingInterestGross	62366000	USD
CY2014Q4	halo	Long Term Debt Interest Gross LongTermDebtInterestGross	12366000	USD
CY2013Q2	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	900000	USD
CY2013Q3	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	6500000	USD
CY2013Q4	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	2600000	USD
CY2013	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	10000000	USD
CY2014	halo	Manufacturingcostspreviouslyrecordedasresearchanddevelopment Manufacturingcostspreviouslyrecordedasresearchanddevelopment	1000000	USD
CY2013Q4	halo	Manufacturingcostspreviouslyrecordedforbulkr Hu Ph20 ManufacturingcostspreviouslyrecordedforbulkrHuPH20	1000000	USD
CY2014	halo	Numberofmanufacturers Numberofmanufacturers	2
CY2014	halo	Period For Termination PeriodForTermination	P90D
CY2013Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	5884000	USD
CY2014Q4	halo	Prepaidmanufacturingexpense Prepaidmanufacturingexpense	6339000	USD
CY2013Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	3522000	USD
CY2014Q4	halo	Prepaidresearchanddevelopment Prepaidresearchanddevelopment	2380000	USD
CY2012Q1	halo	Purchase Of Common Stock By Affiliates PurchaseOfCommonStockByAffiliates	1360000	shares
CY2012Q1	halo	Purchase Of Common Stock By Affiliates Amount PurchaseOfCommonStockByAffiliatesAmount	14400000	USD
CY2012	halo	Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent	0.10
CY2013	halo	Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent	0.10
CY2014	halo	Share Based Compensation Arrangement By Share Based Payment Award Pre Vesting Forfeitures Percent ShareBasedCompensationArrangementByShareBasedPaymentAwardPreVestingForfeituresPercent	0.10
CY2012Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1020000	shares
CY2014Q1	halo	Stock Issued During Period Shares New Issues To Underwriter StockIssuedDuringPeriodSharesNewIssuesToUnderwriter	1153846	shares
CY2013Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3135000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3003000	USD
CY2013Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9707000	USD
CY2014Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	9760000	USD
CY2013Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9097000	USD
CY2014Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	9149000	USD
CY2012	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	0	USD
CY2013	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1116000	USD
CY2014	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-1457000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14369000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13961000	USD
CY2013Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	14920000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	14441000	USD
CY2013Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7649000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9219000	USD
CY2013Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	17000	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-41000	USD
CY2013Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	361930000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	491694000	USD
CY2012	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	8349000	USD
CY2013	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	9538000	USD
CY2014	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15274000	USD
CY2012	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8349000	USD
CY2013	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	9538000	USD
CY2014	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	15274000	USD
CY2013Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2014Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	0	USD
CY2012	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	9000	USD
CY2013	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	156000	USD
CY2014	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	2025000	USD
CY2012	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	7444333	shares
CY2013	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8070141	shares
CY2014	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8405903	shares
CY2013Q4	us-gaap	Assets Assets	101793000	USD
CY2014Q4	us-gaap	Assets Assets	165977000	USD
CY2013Q4	us-gaap	Assets Current AssetsCurrent	95195000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	161321000	USD
CY2013Q4	us-gaap	Available For Sale Securities AvailableForSaleSecurities	44146000	USD
CY2013Q4	us-gaap	Available For Sale Securities Amortized Cost AvailableForSaleSecuritiesAmortizedCost	44129000	USD
CY2013Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	44146000	USD
CY2014Q4	us-gaap	Available For Sale Securities Current AvailableForSaleSecuritiesCurrent	74234000	USD
CY2014	us-gaap	Available For Sale Securities Gross Realized Gain Loss Net AvailableForSaleSecuritiesGrossRealizedGainLossNet	0	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Gains AvailableForSaleSecuritiesGrossUnrealizedGains	20000	USD
CY2013	us-gaap	Available For Sale Securities Gross Unrealized Loss AvailableForSaleSecuritiesGrossUnrealizedLoss	3000	USD
CY2014Q4	us-gaap	Available For Sale Securities In Unrealized Loss Positions Qualitative Disclosure Number Of Positions Less Than One Year AvailableForSaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositionsLessThanOneYear	14
CY2012	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	154000	USD
CY2013	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000	USD
CY2014	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	156000	USD
CY2012	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	1450000	USD
CY2013	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	-1450000	USD
CY2014	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2011Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	52375000	USD
CY2012Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	99501000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	27357000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	61389000	USD
CY2012	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	47126000	USD
CY2013	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-72144000	USD
CY2014	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	34032000	USD
CY2013Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2014Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	4681212	shares
CY2013Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2013Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	114534000	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	125721000	shares
CY2013Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	114534000	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	125721000	shares
CY2013Q4	us-gaap	Common Stock Value CommonStockValue	115000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	126000	USD
CY2012	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-53552000	USD
CY2013	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-83462000	USD
CY2014	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-68433000	USD
CY2014	us-gaap	Concentration Risk Percentage1 ConcentrationRiskPercentage1	0.1
CY2012	us-gaap	Cost Of Goods Sold CostOfGoodsSold	1094000	USD
CY2013	us-gaap	Cost Of Goods Sold CostOfGoodsSold	6246000	USD
CY2014	us-gaap	Cost Of Goods Sold CostOfGoodsSold	22732000	USD
CY2012	us-gaap	Costs And Expenses CostsAndExpenses	95950000	USD
CY2013Q1	us-gaap	Costs And Expenses CostsAndExpenses	30330000	USD
CY2013Q2	us-gaap	Costs And Expenses CostsAndExpenses	36574000	USD
CY2013Q3	us-gaap	Costs And Expenses CostsAndExpenses	34507000	USD
CY2013Q4	us-gaap	Costs And Expenses CostsAndExpenses	33822000	USD
CY2013	us-gaap	Costs And Expenses CostsAndExpenses	135233000	USD
CY2014Q1	us-gaap	Costs And Expenses CostsAndExpenses	37185000	USD
CY2014Q2	us-gaap	Costs And Expenses CostsAndExpenses	33325000	USD
CY2014Q3	us-gaap	Costs And Expenses CostsAndExpenses	33632000	USD
CY2014Q4	us-gaap	Costs And Expenses CostsAndExpenses	34228000	USD
CY2014	us-gaap	Costs And Expenses CostsAndExpenses	138370000	USD
CY2014Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	50000000	USD
CY2014Q4	us-gaap	Debt Instrument Unamortized Discount DebtInstrumentUnamortizedDiscount	140000	USD
CY2013Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1000000	USD
CY2014Q4	us-gaap	Deferred Rent Credit DeferredRentCredit	1000000	USD
CY2013Q4	us-gaap	Deferred Revenue DeferredRevenue	53143000	USD
CY2014Q4	us-gaap	Deferred Revenue DeferredRevenue	54634000	USD
CY2013Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7398000	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	7367000	USD
CY2013Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	45745000	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	47267000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	13324000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	18034000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	162111000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	179159000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2014Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2013Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	143000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	194000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	116572000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	120707000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	853000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	891000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	28867000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	34146000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	2495000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	5381000	USD
CY2013Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	161968000	USD
CY2014Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	178965000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	143000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Noncurrent DeferredTaxLiabilitiesNoncurrent	194000	USD
CY2013Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	143000	USD
CY2014Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	194000	USD
CY2012	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	500000	USD
CY2013	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	600000	USD
CY2014	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	700000	USD
CY2012	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1079000	USD
CY2013	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1227000	USD
CY2014	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1762000	USD
CY2012	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.48
CY2013Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.20
CY2013Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.17
CY2013Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
CY2013	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.74
CY2014Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.22
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2014Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
CY2014Q4	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.04
CY2014	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.56
CY2012	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2013	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2014	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.34
CY2013Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7075000	USD
CY2014Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5923000	USD
CY2014	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	0	USD
CY2013Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2014Q4	us-gaap	Fair Value Assets Level1 To Level2 Transfers Amount FairValueAssetsLevel1ToLevel2TransfersAmount	0	USD
CY2012	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-7000	USD
CY2013	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2014	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-233000	USD
CY2013Q1	us-gaap	Gross Profit GrossProfit	769000	USD
CY2013Q2	us-gaap	Gross Profit GrossProfit	1816000	USD
CY2013Q3	us-gaap	Gross Profit GrossProfit	9342000	USD
CY2013Q4	us-gaap	Gross Profit GrossProfit	6266000	USD
CY2014Q1	us-gaap	Gross Profit GrossProfit	3048000	USD
CY2014Q2	us-gaap	Gross Profit GrossProfit	3570000	USD
CY2014Q3	us-gaap	Gross Profit GrossProfit	4476000	USD
CY2014Q4	us-gaap	Gross Profit GrossProfit	3997000	USD
CY2014	us-gaap	Impairment Of Investments ImpairmentOfInvestments	0	USD
CY2013	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2014	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	200000	USD
CY2012	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2013	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2014	us-gaap	Income Tax Expense Benefit Continuing Operations Discontinued Operations Extraordinary Items IncomeTaxExpenseBenefitContinuingOperationsDiscontinuedOperationsExtraordinaryItems	0	USD
CY2012	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20954000	USD
CY2013	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	33525000	USD
CY2014	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	16998000	USD
CY2012	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2013	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	0	USD
CY2014	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	12747000	USD
CY2012	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-18208000	USD
CY2013	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-28383000	USD
CY2014	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-23247000	USD
CY2012	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	1293000	USD
CY2013	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	5219000	USD
CY2014	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	540000	USD
CY2012	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-3023000	USD
CY2013	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1745000	USD
CY2014	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1761000	USD
CY2012	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	1016000	USD
CY2013	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	8616000	USD
CY2014	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	5277000	USD
CY2012	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-3263000	USD
CY2013	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	7888000	USD
CY2014	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-816000	USD
CY2012	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	13441000	USD
CY2013	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-6606000	USD
CY2014	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	52000	USD
CY2012	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	2962000	USD
CY2013	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	9297000	USD
CY2014	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	1490000	USD
CY2012	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	2103000	USD
CY2013	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	3499000	USD
CY2014	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	236000	USD
CY2012	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4421000	USD
CY2013	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1959000	USD
CY2014	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	265000	USD
CY2012	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	-50000	USD
CY2013	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	100000	USD
CY2014	us-gaap	Increase Decrease In Restricted Cash IncreaseDecreaseInRestrictedCash	0	USD
CY2012	us-gaap	Interest Expense InterestExpense	0	USD
CY2013	us-gaap	Interest Expense InterestExpense	3274000	USD
CY2012	us-gaap	Interest Paid InterestPaid	19000	USD
CY2014	us-gaap	Interest Expense InterestExpense	5581000	USD
CY2013	us-gaap	Interest Expense Debt InterestExpenseDebt	3300000	USD
CY2014	us-gaap	Interest Expense Debt InterestExpenseDebt	5600000	USD
CY2013Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	4280000	USD
CY2014Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	5207000	USD
CY2012	us-gaap	Investment Income Net InvestmentIncomeNet	73000	USD
CY2014Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	553000	USD
CY2013	us-gaap	Interest Paid InterestPaid	3099000	USD
CY2014	us-gaap	Interest Paid InterestPaid	3460000	USD
CY2013Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	753000	USD
CY2014Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	646000	USD
CY2013Q4	us-gaap	Inventory Net InventoryNet	6170000	USD
CY2014Q4	us-gaap	Inventory Net InventoryNet	6406000	USD
CY2013Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	1137000	USD
CY2013	us-gaap	Investment Income Net InvestmentIncomeNet	229000	USD
CY2014	us-gaap	Investment Income Net InvestmentIncomeNet	242000	USD
CY2013Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	49857000	USD
CY2014Q4	us-gaap	Investments Fair Value Disclosure InvestmentsFairValueDisclosure	116919000	USD
CY2014	us-gaap	Lease Expiration Date1 LeaseExpirationDate1	2018-01-31
CY2013Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	101793000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	165977000	USD
CY2013Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24902000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	24331000	USD
CY2012	us-gaap	License And Services Revenue LicenseAndServicesRevenue	39438000	USD
CY2013	us-gaap	License And Services Revenue LicenseAndServicesRevenue	30327000	USD
CY2014	us-gaap	License And Services Revenue LicenseAndServicesRevenue	28086000	USD
CY2013Q4	us-gaap	Long Term Debt LongTermDebt	49772000	USD
CY2014Q4	us-gaap	Long Term Debt LongTermDebt	49860000	USD
CY2014Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	0	USD
CY2014Q4	us-gaap	Long Term Debt Fair Value LongTermDebtFairValue	49860000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3775000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Five LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive	0	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	6501000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	27013000	USD
CY2014Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	25077000	USD
CY2014Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	49860000	USD
CY2012	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	112818000	USD
CY2013	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25064000	USD
CY2014	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	114501000	USD
CY2012	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1413000	USD
CY2013	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-47869000	USD
CY2014	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32951000	USD
CY2012	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-64279000	USD
CY2013	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-49339000	USD
CY2014	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47518000	USD
CY2012	us-gaap	Net Income Loss NetIncomeLoss	-53552000	USD
CY2013Q1	us-gaap	Net Income Loss NetIncomeLoss	-19289000	USD
CY2013Q2	us-gaap	Net Income Loss NetIncomeLoss	-22912000	USD
CY2013Q3	us-gaap	Net Income Loss NetIncomeLoss	-19292000	USD
CY2013Q4	us-gaap	Net Income Loss NetIncomeLoss	-21986000	USD
CY2013	us-gaap	Net Income Loss NetIncomeLoss	-83479000	USD
CY2014Q1	us-gaap	Net Income Loss NetIncomeLoss	-26548000	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-16273000	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-20280000	USD
CY2014Q4	us-gaap	Net Income Loss NetIncomeLoss	-5274000	USD
CY2014	us-gaap	Net Income Loss NetIncomeLoss	-68375000	USD
CY2014	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	Segment
CY2012	us-gaap	Operating Income Loss OperatingIncomeLoss	-53625000	USD
CY2013	us-gaap	Operating Income Loss OperatingIncomeLoss	-80434000	USD
CY2014	us-gaap	Operating Income Loss OperatingIncomeLoss	-63036000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	6519000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	2133000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	82000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	2162000	USD
CY2014Q4	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	2142000	USD
CY2012	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1600000	USD
CY2013	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1700000	USD
CY2014	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1900000	USD
CY2013Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1235000	USD
CY2014Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2023000	USD
CY2013Q4	us-gaap	Other Assets OtherAssets	356000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	1535000	USD
CY2013	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	17000	USD
CY2014	us-gaap	Other Comprehensive Income Loss Before Tax OtherComprehensiveIncomeLossBeforeTax	-58000	USD
CY2012	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	0	USD
CY2013	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	17000	USD
CY2014	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax	-58000	USD
CY2013Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	1364000	USD
CY2014Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	3167000	USD
CY2013Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1339000	USD
CY2014Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	1094000	USD
CY2014	us-gaap	Other Restructuring Costs OtherRestructuringCosts	0	USD
CY2014	us-gaap	Payments For Restructuring PaymentsForRestructuring	700000	USD
CY2012	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	0	USD
CY2013	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	48947000	USD
CY2014	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	88884000	USD
CY2012	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1413000	USD
CY2013	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2297000	USD
CY2014	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1368000	USD
CY2013Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2013Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2013Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	1205000	USD
CY2014	us-gaap	Prior Period Reclassification Adjustment PriorPeriodReclassificationAdjustment	600000	USD
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2013Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2013Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11101000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	11348000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8425000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10143000	USD
CY2013Q4	us-gaap	Prepaid Expense And Other Assets Noncurrent PrepaidExpenseAndOtherAssetsNoncurrent	2676000	USD
CY2012	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	29661000	USD
CY2013	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	19985000	USD
CY2014	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0	USD
CY2012Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81500000	USD
CY2014Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107700000	USD
CY2012	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	81477000	USD
CY2013	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2014	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	107713000	USD
CY2012	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	0	USD
CY2013	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	3375000	USD
CY2014	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	57301000	USD
CY2012	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	1680000	USD
CY2013	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	5079000	USD
CY2014	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6788000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	11071000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12170000	USD
CY2013Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	3422000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2951000	USD
CY2014	us-gaap	Property Plant And Equipment Useful Life PropertyPlantAndEquipmentUsefulLife	P3Y
CY2012	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	70044000	USD
CY2013	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	96640000	USD
CY2014	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	79696000	USD
CY2013Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	500000	USD
CY2014	us-gaap	Restructuring And Related Cost Number Of Positions Eliminated Period Percent RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent	0.13
CY2014Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	500000	USD
CY2013Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-382052000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-450427000	USD
CY2012	us-gaap	Revenues Revenues	42325000	USD
CY2013Q1	us-gaap	Revenues Revenues	11833000	USD
CY2013Q2	us-gaap	Revenues Revenues	14454000	USD
CY2013Q3	us-gaap	Revenues Revenues	16013000	USD
CY2013Q4	us-gaap	Revenues Revenues	12499000	USD
CY2013	us-gaap	Revenues Revenues	54799000	USD
CY2014Q1	us-gaap	Revenues Revenues	11966000	USD
CY2014Q2	us-gaap	Revenues Revenues	18385000	USD
CY2014Q3	us-gaap	Revenues Revenues	14606000	USD
CY2014Q4	us-gaap	Revenues Revenues	30377000	USD
CY2014	us-gaap	Revenues Revenues	75334000	USD
CY2012	us-gaap	Royalty Revenue RoyaltyRevenue	0	USD
CY2013	us-gaap	Royalty Revenue RoyaltyRevenue	33000	USD
CY2014	us-gaap	Royalty Revenue RoyaltyRevenue	9425000	USD
CY2012Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	10.61
CY2014Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	13.00
CY2012	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	2887000	USD
CY2013	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	24439000	USD
CY2014	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	37823000	USD
CY2012	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	24812000	USD
CY2013	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	32347000	USD
CY2014	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35942000	USD
CY2014	us-gaap	Severance Costs1 SeveranceCosts1	1200000	USD
CY2012	us-gaap	Share Based Compensation ShareBasedCompensation	8349000	USD
CY2013	us-gaap	Share Based Compensation ShareBasedCompensation	9538000	USD
CY2014	us-gaap	Share Based Compensation ShareBasedCompensation	15274000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Payments ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendPayments	0	USD
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0115
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0200
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.0204
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0080
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0086
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.0173
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	260722	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	214982	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	1185960	shares
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.34
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	8.18
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	9.39
CY2012	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1215442	shares
CY2013	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1806392	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	2271143	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	11200000	USD
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	5869784	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6379867	shares
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6700915	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	6353892	shares
CY2011Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.82
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber	3944408	shares
CY2012Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.59
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.11
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.18
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	8900000	USD
CY2013	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	7.36
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	10900000	USD
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	6025883	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.05
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.56
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.34
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	5.43
CY2012	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.90
CY2013	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.14
CY2014	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	13.02
CY2012	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y7M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y8M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P4Y7M
CY2014	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y5M
CY2012Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	7820000	shares
CY2014Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	8846153	shares
CY2013	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	461729	shares
CY2014	us-gaap	Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures	789345	shares
CY2012	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	444637	shares
CY2013	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1270362	shares
CY2014	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	1432206	shares
CY2012	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	81477000	USD
CY2014	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	107713000	USD
CY2012	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2013	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2014	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	0	USD
CY2012	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1680000	USD
CY2013	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	5079000	USD
CY2014	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	6788000	USD
CY2011Q4	us-gaap	Stockholders Equity StockholdersEquity	10901000	USD
CY2012Q4	us-gaap	Stockholders Equity StockholdersEquity	48855000	USD
CY2013Q4	us-gaap	Stockholders Equity StockholdersEquity	-19990000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	41352000	USD
CY2014Q4	us-gaap	Undistributed Earnings Of Foreign Subsidiaries UndistributedEarningsOfForeignSubsidiaries	0	USD
CY2012	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2013	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2014	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2011Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	15000	USD
CY2012Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	178000	USD
CY2013Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	610000	USD
CY2014Q4	us-gaap	Valuation Allowances And Reserves Balance ValuationAllowancesAndReservesBalance	609000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	771000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	2979000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Charged To Cost And Expense ValuationAllowancesAndReservesChargedToCostAndExpense	4518000	USD
CY2012	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	608000	USD
CY2013	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	2547000	USD
CY2014	us-gaap	Valuation Allowances And Reserves Deductions ValuationAllowancesAndReservesDeductions	4519000	USD
CY2012	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	111077000	shares
CY2013Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112417000	shares
CY2013Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112486000	shares
CY2013Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112765000	shares
CY2013Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	113550000	shares
CY2013	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	112805000	shares
CY2014Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	118943000	shares
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	123710000	shares
CY2014Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124041000	shares
CY2014Q4	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	124272000	shares
CY2014	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	122690000	shares
CY2014	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk, Sources of Supply and Significant Customers</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to credit risk from our portfolio of cash equivalents and marketable securities. These investments were made in accordance with our investment policy which specifies the categories, allocations, and ratings of securities we may consider for investment. The primary objective of our investment activities is to preserve principal while at the same time maximizing the income we receive without significantly increasing risk. We maintain our cash and cash equivalent balances with one major commercial bank and marketable securities with another financial institution. Deposits held with the financial institutions exceed the amount of insurance provided on such deposits. We are exposed to credit risk in the event of a default by the financial institutions holding our cash, cash equivalents and marketable securities to the extent recorded on the balance sheet. </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are also subject to credit risk from our accounts receivable related to our product sales and revenues under our license and collaborative agreements. We have license and collaborative agreements with pharmaceutical companies under which we receive payments for license fees, milestone payments for specific achievements designated in the collaborative agreements, reimbursements of research and development services and supply of bulk formulation of rHuPH20. In addition, we sell </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant in the United States to a limited number of established wholesale distributors in the pharmaceutical industry. Credit is extended based on an evaluation of the customer’s financial condition, and collateral is not required. Management monitors our exposure to accounts receivable by periodically evaluating the collectibility of the accounts receivable based on a variety of factors including the length of time the receivables are past due, the financial health of the customer and historical experience. </font></div></div>
CY2014	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization and Business</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Halozyme Therapeutics, Inc. is seeking to translate our unique knowledge of the tumor microenvironment to create novel therapies that can improve cancer survival. Our research focuses on human enzymes that alter the extracellular matrix and tumor microenvironment. The extracellular matrix is a complex matrix of proteins and carbohydrates surrounding the cell that provides structural support in tissues and orchestrates many important biological activities, including cell migration, signaling and survival. Over many years, we have developed unique technology and scientific expertise enabling us to pursue this target-rich environment for the development of therapies.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary enzymes can be used to facilitate the delivery of injected drugs and fluids, potentially enhancing the efficacy and the convenience of other drugs or can be used to alter abnormal tissue structures for clinical benefit. We have chosen to exploit our technology and expertise in a balanced way to modulate both risk and spend by: (1) developing our own proprietary products in therapeutic areas with significant unmet medical needs, with a focus on oncology, and (2) licensing our technology to biopharmaceutical companies to collaboratively develop products which combine our technology with the collaborators' proprietary compounds.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The majority of our approved product and product candidates are based on rHuPH20, our patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA), a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage. We believe this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. We refer to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">™</sup></font><font style="font-family:inherit;font-size:10pt;"> technology. rHuPH20 is also the active ingredient in our first commercially approved product, </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Hylenex</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> recombinant.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our proprietary development pipeline consists primarily of clinical stage product candidates in oncology and diabetes. Our lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. When HA accumulates in a tumor, it can cause higher pressure in the tumor, reducing blood flow into the tumor and with that, reduced access of cancer therapies to the tumor. PEGPH20 works by temporarily degrading HA surrounding some cancer cells and results in reduced pressure and increased blood flow to the cancer with increased amounts of anticancer treatments administered concomitantly gaining access to the tumor. We are currently in Phase 2 clinical testing for PEGPH20 in metastatic pancreatic cancer (Study 109-202), and we have recently initiated a clinical trial in non-small cell lung cancer (Study 107-201). </font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Regarding Enhanze, we currently have collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. (Roche), Baxter Healthcare Corporation (Baxter), Pfizer Inc. (Pfizer) and Janssen Biotech, Inc. (Janssen), with one product approved in the U.S. and three products approved for marketing in Europe from which we are receiving royalties and several others at various stages of development.</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Except where specifically noted or the context otherwise requires, references to “Halozyme,” “the Company,” “we,” “our,” and “us” in these Notes to Consolidated Financial Statements refer to Halozyme Therapeutics, Inc. and its wholly owned subsidiary, Halozyme, Inc., and Halozyme, Inc.'s wholly owned subsidiary, Halozyme Holdings Ltd.</font></div></div>
CY2014	us-gaap	Reclassifications Reclassifications	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reclassifications</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain prior period amounts have been reclassified to conform to the current period presentation. Specifically, we have reclassified </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> from accrued expenses to other long-term liabilities in the consolidated balance sheet at December 31, 2013.</font></div></div>
CY2014	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:8px;text-align:justify;text-indent:32px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles (“U.S. GAAP”) requires management to make estimates and assumptions that affect the amounts reported in our consolidated financial statements and accompanying notes. On an ongoing basis, we evaluate our estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from management’s estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001159036-15-000041-index-headers.html	Edgar Link	pending
0001159036-15-000041-index.html	Edgar Link	pending
0001159036-15-000041.txt	Edgar Link	pending
0001159036-15-000041-xbrl.zip	Edgar Link	pending
ex1039secondloanamendment.htm	Edgar Link	pending
ex211subsidiaries2014.htm	Edgar Link	pending
ex23110k2014.htm	Edgar Link	pending
ex31110k2014.htm	Edgar Link	pending
ex31210k2014.htm	Edgar Link	pending
ex3210k2014.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xls	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
halo-12312014x10k.htm	Edgar Link	pending
halo-20141231.xml	Edgar Link	completed
halo-20141231.xsd	Edgar Link	pending
halo-20141231_cal.xml	Edgar Link	unprocessable
halo-20141231_def.xml	Edgar Link	unprocessable
halo-20141231_lab.xml	Edgar Link	unprocessable
halo-20141231_pre.xml	Edgar Link	unprocessable
pipelineslide224152.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
stockprice2014revised2a01.jpg	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q4 Form 10-K Financial Statement

#000115903615000041 Filed on March 02, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO HALOZYME THERAPEUTICS, INC. Stock $halo

2014 Q4 Form 10-K Financial Statement

#000115903615000041 Filed on March 02, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HALO
HALOZYME THERAPEUTICS, INC. Stock $halo